senckađ
Group745
Group745
Group745
Group745
Group745
Group745
EDITION
Global
USA
UK
AUNZ
CANADA
IRELAND
FRANCE
GERMANY
ASIA
EUROPE
LATAM
MEA
Hires, Wins & Business in association withLBB Pro
Group745

Havas Health Appoints Pfizer’s Anna Maria Marra as Europe CEO

12/11/2024
Advertising Agency
New York, USA
89
Share
After over 22 years at Pfizer, Anna Maria Marra will helm Havas Health’s European branch to expand global operations, capabilities and growth

Havas Health has appointed Anna Maria Marra as CEO of Europe to lead and oversee all aspects of the region’s business operations. 

Anna’s prowess for overseeing cross-functional teams and driving global blockbuster pharmaceutical brand launches has solidified her reputation as a leader who can effectively navigate complex markets to drive significant growth. In her new role as Havas Health’s CEO of Europe, Anna will continue to leverage her industry-renowned ability to penetrate different regional markets to deliver client results. 

Her career spans more than 26 years across four continents, during which she has held key leadership roles in marketing, sales, and operations at Organon, MSD, and, most recently, Pfizer. In her previous role, she led the global marketing for Emblaveo®, a novel antibiotic for hospital and specialty care, helping to bring this lifesaving drug to market to support the fight against antimicrobial resistance.  

“My experience has equipped me with deep insight on how to best apply digital trends to marketing innovation on a global and regional scale," shared Anna. "I’ve long admired the work coming out of Havas Health and am thrilled to be joining an organisation at the forefront of healthcare marketing transformation.” 

All European agency CEOs will now report to Anna, and she will report to Donna Murphy, global chief executive officer of Havas Health and Havas Creative Networks.  

“Having Anna Maria onboard to lead Europe will undoubtedly make a meaningful impact on our clients and their businesses,” said Donna. “Her breadth of global brand commercialization and pharmaceutical product expertise will give Havas Health a strategic new edge, and I look forward to seeing all she accomplishes as we gain momentum into 2025.”  

SIGN UP FOR OUR NEWSLETTER
More News from Havas Health
5 minutes with...
5 Minutes with… Chloé Depiesse
12/08/2024
272
0
223
0
ALL THEIR NEWS
Work from Havas Health
ALL THEIR WORK
SUBSCRIBE TO LBB’S newsletter
FOLLOW US
LBB’s Global Sponsor
Group745
Language:
English
v10.0.0